Patritumab Deruxtecan for Untreated HR+/HER2− Early Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
ESMO Open
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Patritumab Deruxtecan in Untreated Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Final Results from Part A of the Window-of-Opportunity SOLTI TOT-HER3 Pre-Operative Study
ESMO Open 2023 May 19;[EPub Ahead of Print], M Oliveira, C Falato, JM Cejalvo, MM Vila, P Tolosa, FJ Salvador-Bofill, J Cruz, M Arumi, AM Luna, JA Guerra, M Vidal, O Martínez-Sáez, L Paré, B González-Farré, E Sanfeliu, E Ciruelos, M Espinosa-Bravo, S Pernas, Y Izarzugaza, S Esker, PD Fan, P Parul, A Santhanagopal, D Sellami, G Villacampa, JM Ferrero-Cafiero, T Pascual, A PratFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.